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Abstract
Angiotensin II (Ang II) plays a major role in the pathogenesis of insulin resistance and diabetes by inhibiting insulin’s
metabolic and potentiating its trophic effects. Whereas the precise mechanisms involved remain ill-defined, they appear to
be associated with and dependent upon increased oxidative stress. We found Ang II to block insulin-dependent GLUT4
translocation in L6 myotubes in an NO- and O2
.2-dependent fashion suggesting the involvement of peroxynitrite. This
hypothesis was confirmed by the ability of Ang II to induce tyrosine nitration of the MAP kinases ERK1/2 and of protein
kinase B/Akt (Akt). Tyrosine nitration of ERK1/2 was required for their phosphorylation on Thr and Tyr and their subsequent
activation, whereas it completely inhibited Akt phosphorylation on Ser
473 and Thr
308 as well as its activity. The inhibitory
effect of nitration on Akt activity was confirmed by the ability of SIN-1 to completely block GSK3a phosphorylation in vitro.
Inhibition of nitric oxide synthase and NAD(P)Hoxidase and scavenging of free radicals with myricetin restored insulin-
stimulated Akt phosphorylation and GLUT4 translocation in the presence of Ang II. Similar restoration was obtained by
inhibiting the ERK activating kinase MEK, indicating that these kinases regulate Akt activation. We found a conserved
nitration site of ERK1/2 to be located in their kinase domain on Tyr
156/139, close to their active site Asp
166/149, in agreement
with a permissive function of nitration for their activation. Taken together, our data show that Ang II inhibits insulin-
mediated GLUT4 translocation in this skeletal muscle model through at least two pathways: first through the transient
activation of ERK1/2 which inhibit IRS-1/2 and second through a direct inhibitory nitration of Akt. These observations
indicate that not only oxidative but also nitrative stress play a key role in the pathogenesis of insulin resistance. They
underline the role of protein nitration as a major mechanism in the regulation of Ang II and insulin signaling pathways and
more particularly as a key regulator of protein kinase activity.
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Introduction
Increasing evidence from in vitro studies and animal models
using ACE inhibitors (ACEI), Ang II AT1 receptor antagonists
(ARB) and more recently renin inhibitors (RI), indicates that Ang
II is involved in insulin resistance [1].
Most important, several clinical trials with ACEI and ARBs
have shown that blockade of the renin-angiotensin system not only
slows down the progression of cardiovascular morbidity and
mortality in type 2 diabetic patients [2] but also reduces the risk of
developing diabetes among hypertensive patients (reviewed in
[3,4]). Even more interesting are the observations that both drug
families have been shown to increase insulin sensitivity [3,4,5,6,7],
indicating that Ang II directly interferes with insulin-dependent
metabolic pathways and therefore probably is involved in the
etiology of diabetes.
Despite the clinical implications of these observations, most
investigators have focused their efforts on studying the interference
of Ang II with insulin signaling pathways in the vascular wall
rather than on major metabolic target tissues like the liver, adipose
tissue and skeletal muscle [1,6]. Several reports on the insulin-
desensitizing effects of Ang II in skeletal muscle indicate that Ang
II reduces insulin-mediated glucose uptake [8,9,10,11,12] and
GLUT4 translocation [9,11,13]. On the other hand, Ang II has
been shown to stimulate the production of reactive oxygen species
(ROS) in endothelial and vascular smooth muscle cells as well as in
various tissues including skeletal muscle in various animal models
[8,11,14] and this pathway has been suggested to play a major role
in its insulin desensitizing effects [1,8,11,14,15].
Although superoxide ions (O2
2.) and hydrogen peroxide (H2O2)
have been reported to affect numerous signaling pathways, the
precise molecular mechanisms through which they alter specific
enzymatic activities have often not been elucidated. With regard to
this question, we have shown previously that ROS-dependent
activation of ERK1/2 by Ang II [16] is in fact due to the
production of the RNS peroxynitrite (ONOO
2), which leads to
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10070their nitration on tyrosine residues [17]. This highly reactive
species results from the reaction of O2
2. with nitric oxide (NO)
and is generated in many pathological conditions which involve
oxidative stress, such as diabetes [18,19,20]. Peroxynitrite can act
both as a strong oxidant, e.g. on lipids which it can peroxidize, and
as a nitrating and S-nitrosating agent on proteins, DNA, lipids and
fatty acids [20,21]. It has also been shown to affect the functional
properties of several proteins including kinases [20] among which
a key enzyme of insulin signaling, Akt [22]. The molecular
mechanism through which ONOO
2 regulates this kinase has
however not been investigated so far although Akt has been
reported to be S-nitrosated in diabetic mice and in response to NO
donors [23,24], indicating that NO and RNS play an important
role in its regulation. As we showed previously that Ang II induces
the nitration rather than the S-nitrosation of other kinases [17],
implying the activation of pathways generating more ONOO
2
than required for S-nitrosation [21], we hypothesized that this
might also be the case with Akt, especially as it has been recently
reported that stimulation of peroxynitrite catalysis restored Akt
phosphorylation and insulin-stimulated glucose uptake in insulin-
resistant mice [25].
The purpose of this study was to clarify the molecular
mechanisms through which Ang II regulates insulin-dependent
Akt activity with regard to glucose uptake in a skeletal muscle
model, differentiated L6 cells.
We found that Ang II completely blocks insulin-stimulated
GLUT4 translocation and strongly inhibits insulin-mediated Akt
phosphorylation on Ser
473 and Thr
308. This effect of Ang II was
ROS- and RNS-dependent. Ang II induced tyrosine nitration of
Akt and this nitration inhibited its phosphorylation as well as that of
its target protein GSK3a. We also found Ang II-activated ERK1/2
to inhibit insulin-dependent Akt activity. Finally, we mapped two
nitration sites of ERK1/2 and found one them to be Tyr
156/139,
located close to the C-loop and the active site Asp
166/149, potentially
in agreement with a permissive function of nitration for their
activation.
Taken together these findings indicate that one of the
mechanisms through which Ang II decreases insulin sensitivity
in skeletal muscle is the inhibition of Akt through at least two
RNS-dependent pathways: first, through the transient activation of
the MEK-ERK1/2 pathway which inhibits IRS1/2-dependent
signaling and second through direct nitration of Akt.
Our data also identify Akt is a novel nitroprotein and further
stress the role of peroxynitrite as a major determinant of insulin
resistance and hence as a potential pharmacological target.
Results
Ang II impairs insulin-mediated translocation of GLUT4
As shown in Fig.1A, insulin (100 nM) stimulated translocation of
the glucose transporter GLUT4 to the plasma membrane
approximately two-fold after 1 hour. Preincubation of L6
myotubes with Ang II (10 nM) for 30 min prior to stimulation
completely abolished insulin-mediated GLUT4 translocation,
which decreased below control levels (P,0.05). The strength of
this inhibition suggests that blockade of this glucose transporter’s
Figure 1. Effect of ROS and RNS modulators on Ang II-regulated insulin-mediated GLUT 4 translocation and Akt phosphorylation.
L6 myotubes were incubated with AEBSF (0.5 mM) for 30 min, 1400 W (10 mM) for 60 min and myricetin (100 mM) for 30 min, prior to incubation
with Ang II (10 nM) for 30 min and subsequent stimulation with insulin 100 nM for 60 min. A: Blots of the plasma membrane or total cell lysate
proteins were probed with anti-GLUT4 antibody. Results are expressed as fold change of untreated control (means 6 s.d.) and the blot is
representative of three independent experiments (*P,0,05 vs control, uP,0,05 vs Ang II + insulin). B: Western blots were probed with anti-
phosphoSer
473-Akt and anti-Akt antibodies. The blot displayed is representative of three independent experiments. Results are expressed as the fold
increase of the ratio of phospho-Akt/Akt over controls (means 6 s.d.) (*P,0,05 vs control, uP,0,05 vs Ang II,
#P,0,05 vs Ang II + Insulin).
doi:10.1371/journal.pone.0010070.g001
Nitration Inhibits Akt
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inhibits glucose uptake in skeletal muscle.
In order to test whether this action of Ang II involves a ROS- or
RNS-dependent pathway, the effect of compounds interfering with
the generation of these reactive species on GLUT4 translocation
was investigated. As shown in the same panel, the Ang II-mediated
inhibition of insulin-dependent translocation was significantly
(P,0.05) alleviated by the NADP(H) inhibitor AEBSF (0.5 mM),
the selective iNOS inhibitor 1400 W (10 mM) and the O2
2.
scavenger myricetin (100 mM), indicating that both NO and O2
2.
generation are involved in this signalling cascade. These
compounds had no significant effect per se on GLUT4
translocation under control or insulin-stimulated conditions but
abolished the effect of Ang II alone (data not shown).
Ang II impairs insulin-mediated phosphorylation of Akt
As Akt is considered to be the upstream regulator of GLUT4
translocation we tested the effect of Ang II on its activation in
response to insulin. This was achieved by determining its level of
phosphorylation on Ser
473 and Thr
308 residues which is known to
be required for its full activation by the upstream kinases PDK1
and mTORC2 and subsequent activation of AS160 which triggers
GLUT4 translocation.
As expected, treatment of myotubes with 100 nM insulin
induced phosphorylation of Akt on both residues in a time-
dependent manner with a maximum reached within 60 min of
incubation (Fig. 2A and B). Interestingly, phosphorylation of Ser
473
was more persistent than that of Thr
308 ($120 min. vs. 60 min.),
suggesting partial inactivation of the enzyme after 1 hour.
Incubation of the myotubes with 10 nM Ang II alone decreased
Akt phosphorylation on Ser
473 below control levels and inhibited
insulin-mediated phosphorylation on both Ser
473 and Thr
308 by
more than 80% (Fig. 2C, D). The magnitude of this effect strongly
suggests that the inhibition of Akt phosphorylation plays a major
role in the impairment of GLUT4 translocation by Ang II.
Effect of ROS and RNS modulators on the inhibition of
insulin-mediated phosphorylation of Akt by Ang II
Since NAD(P)H-oxidase and NOS inhibitors and a free radical
scavenger significantly restored Ang II-induced inhibition of
GLUT4 translocation to the plasma membrane (Fig. 1A), we
examined the effect of sensitivity of these ROS and RNS
modulators on Ang II-mediated inhibition of Akt phosphorylation
in order to verify whether the pathway involved might be the
same. As expected, 1400 W, AEBSF and myricetin almost
completely suppressed Ang II-induced inhibition of insulin-
mediated Akt phosphorylation on Ser
473 (Fig. 1B). Identical results
were obtained for Thr
308 phosphorylation (data not shown). These
data indicate that, as observed for GLUT4 translocation, NO and
O2
2. generation are required for the inhibition of Akt phosphor-
ylation by Ang II. Likewise Ang II inhibited basal Akt
phosphorylation below control levels (P,0.05) and the ROS and
RNS modulators used restored basal phosphorylation (data not
shown).
Nitration of Akt in response to Ang II
NO and O2
2. are known to react yielding the RNS
peroxynitrite. The absolute requirement of NO and O2
2.
generation for the inhibition of Akt phosphorylation (Fig. 1B)
and the subsequent translocation of GLUT4 (Fig. 1A), prompted
us to verify whether Akt might be a direct target of this reactive
species.
As shown in Fig. 3, exposure of L6 myotubes to 10 nM Ang II,
resulted in the ability of an anti-nitrotyrosine antibody to
immunoprecipitate Akt. This tyrosine nitration was time-
dependent, occurring within 10 minutes and peaking at 60 min
(approximately 4-fold increase as compared to control), thus
indicating a significant nitration of the enzyme in response to
Ang II. Nitration levels were back to control values within
120 min. These observations thus confirm the hypothesis that
Ang II induces the generation of NO and O2
2. in myotubes
resulting in the formation of peroxynitrite. They also indicate
that Akt is a target of this reactive species and is thus a novel
nitroprotein.
Effect of ROS and RNS modulators on insulin-stimulated
Akt activity in cellulo
Although phosphorylation of Ser
473 and Thr
308 residues is
generally used as a marker of Akt activation, we directly measured
its enzymatic activity by determining its ability to phosphorylate
GSK3a which is one of its known targets. L6 myotubes were
incubated with the hormones and modulators used previously and
Akt was immunoprecipitated. The immunoprecipitated Akt was
incubated in vitro with recombinant GSK3a inthepresenceofAT-
Pand the phosphorylation of this kinase on Ser
21 was determined
by immunoblotting.
As shown in Fig. 4A, insulin (100 nM) stimulated Akt-mediated
GSK3a phosphorylation approximately 10-fold and this effect was
totally blocked by Ang II. Ang II by itself reduced GSK3a
phosphorylation below control levels (P,0.05) as observed for Akt
phosphorylation (Fig. 2C&D ). Likewise, the ROS and RNS
modulators alleviated the inbitory effect of Ang II on insulin-
mediated activation (Fig. 4A). Interestingly, whereas the
NADP(H)-oxidase inhibitor AEBSF and the ROS scavenger
myrecitin only partly restored Akt activity, the NOS inhibitor
1400 W completely obliterated the effect of Ang II.
These data show that there is an excellent agreement between
the phosphorylation of Akt on Ser
473 and Thr
308 and its activity as
determined by its ability to phosphorylate GSK3a (Fig. 2). They
also indicate that the inhibitory effect of Ang II involves a
mechanism preventing not only phosphorylation of Akt on Ser
473
and Thr
308 but also its catalytic activity.
In vitro nitration of Akt inhibits its activity
These observations together with those showing that Akt is
nitrated in response to Ang II (Fig. 3), raised the question as to
whether this nitration directly affects Akt activity or whether it is
rather an associated phenomenon which may have other
functions, the inhibition being then due to the nitration of other
more upstream targets.
In order to test this, we nitrated recombinant Akt in vitro using
SIN-1, a compound which spontaneously degrades into NO and
O2
2. yielding peroxynitrite. Nitrated Akt was incubated with
recombinant GSK3a whose phosphorylation on Ser
21 in vitro was
determined by immunoblotting.
As shown in Fig. 4B, non-nitrated recombinant phospho-Akt
heavily phosphorylated GSK3a, whereas prior exposure to SIN-1
inhibited this in a dose-dependent manner. In order to further
verify whether the inhibitory effect of the peroxynitrite donor was
indeed linked to Akt nitration, the blots were probed with an anti-
nitrotyrosine antibody which labelled a band corresponding to Akt
only when SIN-1 was added (Fig. 4B). The degree of Akt nitration
was dose-dependent and as expected, inversely related to GSK3a
phosphorylation. This observation clearly indicates that Akt
nitration is sufficient to fully inhibit its activity.
Nitration Inhibits Akt
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phosphorylation of Akt in the presence of Ang II
The observation that nitration inhibits Akt does however not
preclude the possibility that other pathways depending on NO and
O2
2. and therefore probably on ONOO
2 generation, may be
involved in the inhibitory action of Ang II. Among these, ERK 1/2
have been reported to inhibit Akt activation [26]. As we have
previously shown Ang II to activate ERK1/2 in an NO and O2
2.-
dependent fashion which proved to be the result of their nitration
[17]. We therefore verified whether this pathway might also be
involved in Ang II-mediated Akt inhibition in myotubes. In order to
Figure2.Kineticsofinsulin-inducedAktphosphorylation andinhibitoryeffectofAng IIoninsulin-inducedAktactivation.L6myotubes
were exposed to insulin (100 nM) for 0–120 min. Blots were probed with anti-Akt and anti-phosphoSer
473-Akt (A) or anti-phosphoThr
308-Akt (B). L6
myotubes were pretreated with Ang II 10 nM for 30 min and stimulated with insulin (100 nM) for 60 min. Blots were probed with anti-Akt and anti-
phosphoSer
473-Akt (C) or anti-phosphoThr
308-Akt (D) antibodies. Results are expressed as fold change of the ratio of phospho-Akt/Akt over controls
(means 6 s.d.) and the blots are representative of three independent experiments (*P,0,05 vs control, uP,0,05 vs Ang II,
#P,0,05 vs Ang II + insulin).
doi:10.1371/journal.pone.0010070.g002
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specific inhibitor U0126. As shown in Fig. 5, U0126 added to the cells
prior to treatment with Ang II and insulin, totally restored insulin-
induced Akt phosphorylation, indicating that this cascade is involved
in the inhibition of Akt by Ang II in this model. U0126 had no effect
on basal or insulin-stimulated Akt phosphorylation (data not shown).
Ang II induces nitration and NO and O2
2.-dependent
activation of ERK 1/2
In order to further verify whether the ERK pathway is indeed
involved in the NO and O2
2.-dependent inhibition of Akt, we tested
whether their activation by Ang II in these myotubes is accompanied
by their tyrosine nitration like in vascular smooth muscle cells [17]
and whether it is affected by ROS and RNS modulators.
Fig. 6A shows that Ang II is able to activate ERK 1/2 in L6
myotubes, as determined by its ability to induce their phosphorylation
on Thr
202/183 and Tyr
204/187 with characteristic kinetics. This
activation is accompanied by their nitration following the same kinetic
pattern (Fig 6B). Further confirming the relationship between ERK
nitration and activation, the ROS modulators 1400 W, AEBSF and
myrecitin all significantly inhibited Ang II-mediated phosphorylation.
Together with the finding that the MEK inhibitor U0126
alleviates Ang II-mediated Akt inhibition, these observations
clearly indicate that the ERK pathway contributes to the
inhibition of Akt in this model.
Mapping of nitrated tyrosines in ERK1
As the molecular mechanism through which tyrosine nitration
regulates kinase activity is still unclear, we tried to map the
nitration sites in both ERK 1 and Akt1 in order to see whether
their location may give some clues. Both recombinant human
enzymes were nitrated in vitro with SIN-1 and digested with
trypsin and chymotrypsin. The tryptic fragments were immuno-
purified with an anti-nitrotyrosine antibody and analyzed by
MALDI-TOF mass spectrometry. Whereas we were unable to
analyze nitrated Akt peptides due to digestion and ionization
problems, we identified two peptides displaying a mass difference
of +45 by MS analysis, corresponding to the adjunction of a nitro
group with ERK1. The peptides with monoisotopic masses of resp.
1552.91 Da and 2749.28 Da correspond to aminoacids 153 – 165
(GLKYIHSANVLHR) and 109–131 (ASTLEAMRDVYIVQDL-
METDLYK). The first peptide contains only one Tyr (Fig. 7A)
indicating a nitration site on Tyr
156, corresponding to Tyr
139 in
ERK2, whereas the second peptide contains two Tyr residues of
which only one was nitrated as indicated by the difference in mass
(Fig. 7B). We were unable to obtain a complete fragmentation of
this peptide for sequencing and could therefore not determine so
far which of Tyr
119 or Tyr
130 corresponds to the nitration site in
this sequence. No corresponding site exists in ERK2. Interestingly,
Tyr
156 which is conserved in ERK2 (Tyr
139), is located in the a-
helix E, close to b6 and the C-loop which contains the active site
Asp
166 with which it might interact.
Discussion
Since the CAPPP trial reported in 1999 that an ACE inhibitors
significantly reduce the risk of developing diabetes as compared to
other antihypertensive treatments (b-blockers, diuretics or a
combination of both), numerous other trials have confirmed the
Figure 3. Kinetics of Ang II-mediated Akt nitration. L6 myotubes were exposed to Ang II (10 nM) for 0–120 min. Western blot of nitrated
proteins from the soluble fractions were immunoprecipitated with anti-nitrotyrosine antibody and probed with anti-Akt antibody. Results are
expressed as the fold increase over controls (means 6 s.d.) and the blot is representative of three independent experiments (*P,0,05 vs. control).
doi:10.1371/journal.pone.0010070.g003
Nitration Inhibits Akt
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II receptor antagonists as compared to other available blood
pressure lowering drugs [2,3,4,5,27]. These trials have prompted
research in this area and numerous authors have since reported
the ability of these drugs to restore or at least improve insulin
sensitivity in diabetic animal models [1,28] and human subjects
[3,7,15,27,29,30]. Several reports indicate that the anti-insulinic
actions of Ang II are mediated, at least in part, through increased
generation of ROS, in particular O2
.2 [1,8,11,15,31,32,33].
Although the pathogenesis of type 2 diabetes is obviously complex
and multifactorial, there is evidence that oxidative stress plays an
etiologic role as it is associated with hyperglycemia, hypertriglyc-
eridemia, obesity, and hypertension [1,14,15,31,34] which all
occur in this disease. Moreover, NAD(P)Hoxidases which
contribute to O2
2 generation are upregulated in type 2 diabetes
[34,35].
Whereas oxidative stress usually evokes the activation of the
O2
.2-H 2O2 -O H
. generation cascade, O2
2. can also give rise to
the generation of RNS such as N2O3,N O
+,N O 2
. and ONOO
2,
depending upon the NO/O2
2. ratio [21]. Accordingly, the
deleterious effects of iNOS, which generates high levels of NO,
on insulin sensitivity have been demonstrated more than a decade
ago by the seminal work of Marette and coworkers [36,37].
ONOO
2 which can affect DNA, lipids and proteins [20,21], gives
rise to nitrative stress which has gained much interest during the
past few years as it has been reported to be involved in various
signaling pathways and hence in a growing number of diseases
[20,38,39,40] including diabetes [18,19,25,41,42]. Peroxynitrite
Figure 4. Effect of ROS and RNS modulators and of nitration on Akt ativity. A: L6 myotubes were pretreated with either AEBSF (0.5 mM) for
30 min, 1400 W (10 mM) for 60 min or myricetin (100 mM) for 30 min prior to addition of Ang II (10 nM) for 30 min and subsequent stimulation with
insulin 100 nM for 60 min. The activity of Akt immunoprecipitated from the cell lysates was determined by its ability to phosphorylate GSK3a.
Western blots were probed with anti-phosphoSer
21-GSK3a. The blot displayed is representative of three independent experiments. Results are
expressed as the fold increase over controls (means 6 s.d.) (*P,0,05 vs control, uP,0,05 vs Insulin,
#P,0,05 vs Ang II,
1P,0,05 vs Ang II + Insulin). B:
Recombinant human PKB/Akt1 (1.5 mg) was nitrated with SIN-1 (1, 10 and 100 mM) for 1 hour at 30uC, immunoprecipitated and incubated with GST-
GSK-3a peptide in the presence of Mg
++/ATP for 2 hours. Blots were probed with a polyclonal rabbit anti-phosphoSer
21-GSK-3a and a monoclonal
mouse anti-nitrotyrosine antibody. The blots are representative of three independent experiments.
doi:10.1371/journal.pone.0010070.g004
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modify the functional properties of several proteins
[17,20,21,38,43]. Increased protein nitration has been shown to
occur in the mitochondria of diabetic mice [19] and nitrated
proteins have been found in plasma of diabetic patients [41,42,44].
Interestingly, Ang II has been shown to stimulate the generation
of peroxynitrite [33,39,45,46,47] and ARBs have been reported to
selectively inhibit iNOS and NAD(P)Hoxidase expression and
activity as well as nitrative stress in both type 1 and 2 diabetic
animal models [1,14,32,33]. Confirming the significance of
ONOO
2 generation, we have shown that Ang II stimulates the
nitration of MEK 1 and ERK 1/2 [17].
These observations have prompted us to investigate the
potential role of Ang II-mediated nitration on the metabolic
pathways of insulin involved in glucose uptake in skeletal muscle.
We report here that Ang II impairs insulin-mediated GLUT4
translocation (Fig. 1A) and inhibits the phosphorylation of Akt
(Fig. 2C&D ) which acts as a common upstream activator of most
of insulin’s metabolic actions including glucose uptake. Previous
reports have shown that Ang II is able to modulate insulin-
Figure 5. Effect of the MEK inhibitor U0126 on insulin-stimulated Akt phosphorylation. L6 myotubes were treated with U0126 (10 mM) for
30 min prior to addition of Ang II (10 nM) for 30 min with subsequent stimulation by insulin 100 nM for 60 min. Western blots were probed with
anti-phosphoSer
473-Akt and anti-Akt antibodies. The blot is representative of three independent experiments. Results are expressed as the fold
increase of the ratio of phospho-Akt/Akt over controls (means 6 s.d.). (*P,0,05 vs control,
#P,0,05 vs Ang II + Insulin).
doi:10.1371/journal.pone.0010070.g005
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increased production of ROS [1,6,48]. We show here that in L6
myotubes, a skeletal muscle model, Ang II induces the nitration of
Akt (Fig. 3) and that this nitration inhibits the kinase’s activity
(Fig. 4). In agreement with a regulation of Akt by RNS, previous
reports indicate that Akt is inhibited by S-nitrosation of its Cys
22 in
insulin resistance [23,24]. S-nitrosylation or nitrosation is the
modification of sulfhydryl (-SH) to S-nitroso (-SNO) groups and
appears to occur at a molar NO/O2
.2 ratio of 2 to 3 [49], which
probably corresponds to the physiological redox status [21,50]. S-
Figure 6. Kinetics of Ang II-dependent phosphorylation and nitration of ERK 1/2. L6 myotubes were exposed to Ang II (10 nM) for 0–
120 min. (A) Blots were probed with anti-phosphoERK1/2 and anti-ERK1/2 antibodies. (B) Samples were immunoprecipitated with anti-nitrotyrosine
antibody and probed with anti-Akt antibody. (C) Effect of ROS and RNS modulators on ERK 1/2 phosphorylation. L6 myotubes were pretreated with
either AEBSF (0.5 mM) for 30 min, 1400 W (10 mM) for 60 min or myricetin (100 mM) for 30 min, prior to addition of Ang II (10 nM) for 30 min and
subsequent stimulation with insulin 100 nM for 60 min. Western blots were probed with anti-phosphoERK and anti-ERK antibodies. The blots are
representative of three independent experiments. Results are expressed as the fold increase of the ratio of phospho-ERK/ERK over controls (means 6
s.d.) (*P,0,05 vs control, uP,0,05 vs Ang + Insulin,
#P,0,05 vs 1400 W + Ang,
+P,0,05 vs AEBSF + Ang,
‘
P,0,05 vs Myricetine + Ang).
doi:10.1371/journal.pone.0010070.g006
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rapidly and spontaneously reversible posttranslational modifica-
tion. Interestingly, one of the reports indicates that increasing the
level of O2
.2, also increased the inhibition of Akt by the pure nitric
oxide donor SNAP [23]. Although the authors did not investigate
the potential tyrosine nitration of Akt under these conditions, it
was most likely to occur since increasing concentrations of O2
.2 in
the presence of NO tends to shift the production of nitrosating
species (NO
+ and/or N2O3) towards peroxynitrite which selec-
tively nitrates tyrosine residues [20,21,49,50]. One can thus
reasonably speculate that these latter conditions generated a
nitrative rather than or parallel to a nitrosative stress. Since Ang II
has been shown to induce oxidative and nitrative stress at
physiological and low nanomolar concentrations, tyrosine nitra-
tion rather than S-nitrosation appears to be the most likely
mechanism of Akt inhibition by this peptide in our model. This
hypothesis is confirmed by our data which show firstly the
restoration of its activity by the blockade of NO and O2
.2
generation (Fig. 4A) and secondly, its tyrosine nitration and
consequent loss of catalytic activity (Fig. 3 & 4B). In addition,
whereas the effect of compounds acting either on the production
or the scavenging of O2
.2, like the NAD(P)Hoxidase inhibitor
AEBSF and the scavenger myricetin, indicate that increased
oxidative stress is involved in this process (Fig. 4A), the effect of the
selective iNOS inhibitor 1400 W (Fig. 4A), shows that nitric oxide
is also required, confirming that Akt inhibition depends on the
reaction products of both O2
2. and nitric oxide and not solely on
O2
.2.
As indicated above, S-nitrosation is a modification which is
rapidly reversible by reduction and which therefore probably is a
Figure 7. Mass spectra of tryptic peptides of nitrated ERK1. Tryptic peptides of nitrated recombinant ERK1 were immunoprecipitated with
anti-nitrotyrosine antibodies. A: Mass spectrum (500–3000 Da) shows a major peak with a monoisotopic mass of 1552.91 corresponding to GLKY
156-
(NO2)IHSANVHR. B: Detailed spectrum (2742–2755.5 Da) shows a major peak with a monoisotopic mass of 2749.28 corresponding to the peptide
ASTLEAMRDVYIVQDLMETDLYK containing one nitrated Tyr, Tyr
119 or Tyr
130. Other peaks correspond to peptides which do not contain Tyr and were
adsorbed non-specifically to the anti-nitrotyrosine agarose beads.
doi:10.1371/journal.pone.0010070.g007
Nitration Inhibits Akt
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variations of O2
.2 production which is well below that of NO
under physiological conditions [21,51]. Conversely, peroxynitrite
generation requires equimolar concentrations of O2
.2 and
therefore only occurs when specific generating enzymes or
systems, e.g. NADP(H)-oxidases, xanthine oxidase, mitochondrial
complexes I and III or iNOS, are activated. This occurs in
response to various signals including hormones and cytokines as
well as pathological conditions like hypoxia, ischemia, hypo- and
probably hyperglycemia [20,34,38,40,42]. In addition, tyrosine
nitration is stable and most likely requires an enzyme to be
reversed [52,53]. It is therefore much more likely to exert
deleterious effects than S-nitrosation. As an example of this
hypothesis, we have recently reported that albumin is nitrated in
newborns who suffered perpartal asphyxia and that the levels of
plasma nitroalbumin are highly correlated to the severity of the
ensuing cerebral lesions [40].
Although the intramolecular interactions involved in the
phosphorylation and activation of Akt are extremely complex, the
interactions of its pleckstrin homology (PH) domain and the
hydrophobic motif (HM; Phe
469-X-X-Phe
472-Ser
473-Tyr
474) of its
C-terminal part with the kinasedomainappear to play a crucial role
[54]. It has been proposed that the HM plays a dual role in the
regulationof Aktactivity dependingupon eitherits bindingto Trp
80
or its burying in the hydrophobic groove. Interestingly, this motif
contains a Tyr residue at position 474. It is therefore conceivable
that if this Tyr were to be nitrated, it may switch the kinase from the
active to the inactive state by increasing its hydrophilicity.
Moreover, this Tyr has also been reported to be phosphorylated,
this modification being required for the full activation of Akt [55].
There are however 15 other Tyr residues in Akt1, 3 of which are
located in the PH domain and 11 in the kinase domain. Among the
latter is Tyr
272 located next to Arg
273 which is believed to be in
contact with the primary phosphate of ATP and to Asp
274 which is
assumed to be the active site [56]. Nitration of this Tyr might thus
alsointerferewithATPbinding.Obviously, mappingof the nitrated
Tyr residue(s) will be necessary to understand the intramolecular
interactions resulting from this posttranslational modification.
As stated earlier, direct nitration of Akt does however not
preclude the existence of other pathways contributing to its
inactivation by Ang II.
Among the other pathways which might potentially be involved
in the inhibition of Akt activity, Sinha et al. previously reported the
involvement of the ERK through the formation of an inhibitory
complex with Rsk and PDK1-bound Akt in renal tubular cells
[26]. Another group reported that Ang II inhibits insulin-mediated
glucose uptake in VSMC through Ser
307 and Ser
616 phosphory-
lation of insulin-receptor substrate-1 by ERK and JNK [57]. Since
we had previously shown that Ang II-mediated ERK activation in
VSMC requires its nitration [17], we tested their putative
involvement in skeletal muscle cells. We found the MEK inhibitor
U0126 to almost completely restore insulin-dependant Akt
activation in the presence of Ang II (Fig. 5), thus indicating the
contribution of the MEK – ERK pathway to the inhibition of Akt
in this model. Interestingly, enhanced ERK activation has also
been reported in skeletal muscle of women with polycystic ovary
syndrome where it has been found to be linked to insulin resistance
[58]. A third potential pathway involving ERK has been proposed
by Skidgel’s group. They reported that in endothelial cells, kinin
B1 receptors activate iNOS via ERK-mediated phosphorylation of
its Ser
745 [59,60]. This pathway may obviously result in increased
ONOO
2 generation and hence, potentially in Akt nitration. This
pathway is likely to be involved in our model as well, since
inhibition of MEK almost completely restores Akt activity (Fig. 5).
Further supporting this hypothesis, is the fact that we found
nitration to be sufficient to completely inhibit recombinant
phosphoSer
473 Akt which is partly active [61] (Fig. 6B).
Similar to VSMC [17], we found Ang II-mediated ERK
activation to require tyrosine nitration as it is abolished by
1400 W, AEBSF, and myricetin in myotubes (Fig. 6C). We
mapped the nitration sites of ERK1 and found them to correspond
to Tyr
156/139, located in the kinase domain of both ERK1 and
ERK2, and Tyr
119 or Tyr
130, expressed only in ERK1 (Fig. 7).
These observations thus further support the hypothesis that
nitration plays a major role in Ang II-mediated Akt inhibition
(Fig. 8) even if they do not rule out the potential role of other
oxidative processes such as S-nitrosation.
These observations all point towards a major role of nitrative
stress and protein nitration in the pathogenesis of insulin resistance
and its complications. Our data provide two novel targets, ERK1/2
and Akt, of a pathological nitrative stress resulting in the
impairment of glucose uptake in skeletal muscle. In agreement
withcell and animalstudies aswell as clinical trials they also confirm
the deleterious effects of Ang II which acts both in a chronic fashion
by increasing the expression of NAD(P)Hoxidase and iNOS and in
acute manner by activating them thereby leading to increased
nitrative stress. The activation mechanisms of iNOS are obviously
very complex and involves interactions with multiple proteins [62]
including Rac2 [63], Src [64] and Ga subunits [65] which can be
triggered by Ang II AT1 receptors. The recent reports by Skidgel’s
group [59,60] suggesting the involvement of ERK are supported by
our observations and further strengthen the role of this enzyme in
G-protein coupled receptor signaling pathways such as Ang II and
kinins. Interestingly, ACE inhibitors, which inhibit Ang II
production from Ang I, also increase the levels of kinins, which
are normally degraded by ACE. Skidgel’s findings therefore imply
that ACE inhibitors, which are also allosteric agonists of B2R
receptors, may result in the inhibition of Akt through the activation
of iNOS. Whether this effect outweighs the inhibition of the Ang II-
dependent effects remains to be determined, but if this is indeed the
case it would suggest that AT1 receptor antagonists would be
superior to ACE inhibitors in preventing or reducing insulin
resistance.Sofar,clinicaltrialscomparingbothclassesofdrugshave
failed to show significant differences on glucose metabolism
[66,67,68], but more sophisticated analysis of glucose tolerance in
these patients would be required to verify this.
Whereas ARBs and ACEI have demonstrated their efficiency in
improving insulin sensitivity and reducing end-organ damage and
are now often considered as first-line therapy in hypertension with
metabolic syndrome or diabetes [3,4,5,30], association of anti-
oxidants or anti-nitrants in an attempt to further reduce
deleterious nitrative stress might be worth considering in severely
affected or non-responsive patients.
Materials and Methods
Reagents
Ang II was from Bachem, myricetin, SIN-1 and nitro-l-arginine-
methyl-ester (L-NAME) from Cayman, insulin and 3-nitrotyrosine
were purchased from Sigma. 4-(2-Aminoethyl) benzenesulfonyl
fluoride (AEBSF) and Chemiluminescence reagent were from
Uptima, Interchim. 1400 W and Trolox were from Acros
Organics. The MEK inhibitor U0126 was from Cell Signaling
Technology. Active recombinant human PKB/Akt1 was from
Assay Designs and the Akt activity immunoassay kit from
Calbiochem. Dulbecco’s modified Eagle’s Medium (containing
1 g/L glucose, pyruvate and glutamax I), fetal bovine serum (FBS),
horse serum (HS) and other cell culture reagents were purchased
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reagents were of analytical grade.
Antibodies
Antibodies directed against Akt, phosphoSer
473-Akt, phos-
phoThr
308-Akt and diphosphoERK (ERK1/2) were purchased
from Cell Signaling Technology. Anti-ERK1/2 antibody was
from Sigma. Anti-GLUT4 antibody was from Biogenesis. Affinity-
purified polyclonal anti-nitrotyrosine antibodies were obtained as
described previously [40]. A monoclonal anti-nitrotyrosine
antibody (clone 2E11) was obtained from Antibodies-online.
Anti-HRP-conjugated anti-rabbit and anti-mouse IgG antibodies
were from Jackson Immunology LaboratoriesH.
Cell Culture
L6 rat skeletal muscle cells (American Type Culture Collection)
were grown in DMEM (1 g/L glucose) containing 20% (v/v) of
fetal bovine serum (FBS) and gentamycin (10 mg/ml) at 5% CO2
in 37uC until 80–90% confluence. Myoblasts were differentiated
into myotubes by replacing FBS with 2% horse serum for 6–8
days. Cells of passages 3–6 were used for experiments.
GLUT4 translocation
Subcellular fractionation of myotubes was carried out as
described by Yonemitsu et al. [69] with slight modifications.
The cells from 10-cm dishes were gently scraped, centrifuged
(1000 x g for 10 min) at 4uC. All subsequent steps were carried out
at 4uC. Cells were resuspended in buffer containing 250 mM
sucrose, 5 mM NaN3, 2 mM EGTA, 20 mM HEPES pH 7.4,
and a protease inhibitor cocktail, as described above, and
homogenized using 20 strokes of a Dounce homogenizer. The
homogenate was centrifuged at 760 x g for 5 min to remove nuclei
and unbroken cells. The supernatant was centrifuged at 30000 x g
for 60 min to pellet the crude plasma membrane fraction. Plasma
Figure 8. Schematic representation of the putative mechanisms involved in the regulation of Akt activity by insulin and Ang II.
Activating pathways are shown in green and inhibitory mechanisms in red.
doi:10.1371/journal.pone.0010070.g008
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PAGE, blotted on PVDF membrane and probed with anti-
GLUT4 antibody.
Immunoprecipitations and immunoblotting
For immunoprecipitation, 50 mg of cell lysate protein was
incubated overnight at 4uC with anti-nitrotyrosine antibody
covalently coupled to agarose beads according to the manufa-
turer’s protocol (CarboLink, PierceH). Covalent hydrazone bonds
were stabilized by reduction with NaCNBH3. For immunoblot-
ting, samples were subjected to 10% SDS-PAGE and transferred
to a PVDF membrane (Perkin Elmer Life Sciences IncH.).
Membranes were blocked with TBST (Tris 50 mM, NaCl
100 mM, pH 7.4, Tween 20 0.1%) containing 5% milk and
probed with the antibodies indicated in the figure legends and
appropriate HRP-labeled secondary antibodies. The blots were
revealed by enhanced chemiluminescence. Densitometric analysis
was performed using Scion Image software.
PKB/Akt activity assays
PKB/Akt activity assays were performed according to the
manufacturer’s protocol using either 100 mg of L6 cell lysate
protein or 0.5 mg of recombinant human active PKB/Akt1
nitrated with SIN-1 in buffer containing 50 mM Tris (pH 7.4)
and 100 mM NaCl for 1 hour at 25uC. Active recombinant Akt1
corresponds to Akt1 purified from extracts of Sf9 cells co-
expressing full-length human Akt1 and mTOR.
Briefly, PKB/Akt was immunoprecipitated and incubated with
a GST fusion protein comprising the GSK-3a phosphorylation
sequence in the presence of Mg
++/ATP. Samples were subjected
to 12% SDS-PAGE and transferred to a PVDF membrane (Perkin
Elmer Life Sciences). Membranes were blocked with TBST (Tris
50 mM, NaCl 100 mM, pH 7.4, Tween 20 0.1%) containing 5%
milk and probed with an anti-phosphoSer
21-GSK-3a followed by
an HRP-labeled anti-rabbit antibody. The blots were revealed by
enhanced chemiluminescence.
Mapping of nitrated tyrosine residues by mass
spectrometry analysis
Recombinant human ERK1-GST (Upstate Biotech) was
nitrated with 100 mM SIN-1 in buffer containing 20 mM MOPS
(pH 7.2), 25 mM b–glycerol phosphate, 5 mM EGTA, 1 mM
sodium orthovanadate, with 15 mM MgCl2 and100 mM ATP for
2 hours at 20uC. After nitration, the GST was cleaved with
thrombin-agarose (SigmaH) according to the manufacturer’s
protocol. GST was removed by glutathione-agarose (PierceH)
affinity chromatography. The nitrated ERK samples were digested
with trypsin (PromegaH) at 25 ng/ml during 2 h. The samples
were diluted in 25 mM ammonium bicarbonate (pH 7.4) with
50 mM NaCl and then incubated in the presence of 20 ml agarose-
conjugated anti-nitrotyrosine antibodies. The nitrated peptides
were eluted with 50% acetonitrile/0.2% trifluoroacetic acid, dried,
resuspended in 1.5 ml of matrix suspension (4 mg a-cyano-4-
hydroxycinnamic acid, 0.8 mg 3,5-dihydroxybenzoic acid in 50%
acetonitrile/0.1% trifluoroacetic acid, 0.1 mM fucose), and
deposited on a stainless steel target. Mass spectrometry analysis
was performed on a Q-TOF Ultima Global mass spectrometer
(MicromassH) equipped with a MALDI source. Ionization was
achieved using a nitrogen laser (337 nm beam, 10 Hz). The
instrument was externally calibrated using the monoisotopic
masses of tryptic and chymotryptic peptides from bovine serum
albumin. Acquisitions were performed in a V-mode reflectron
position. Microsequencing was performed by argon-induced
fragmentation after selection of the parent ion.
Statistical analysis
Statistical analysis was performed by one-way ANOVA
followed by the Holm-Sidak method for comparison between
groups. P,0.05 was considered to be statistically significant. Error
is represented as standard deviation.
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